Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation

Blood Adv. 2018 Oct 9;2(19):2550-2553. doi: 10.1182/bloodadvances.2018020883.

Abstract

New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.

Publication types

  • Case Reports

MeSH terms

  • Anemia, Hemolytic, Autoimmune / diagnosis
  • Anemia, Hemolytic, Autoimmune / mortality
  • Anemia, Hemolytic, Autoimmune / therapy*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Biomarkers
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Infant
  • Male
  • Retrospective Studies
  • Transplantation, Homologous
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • daratumumab